A new weapon in the fight against osteoarthritis?
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating osteoarthritis. This is based on a polysaccharide, a long-chain sugar molecule, originating from brown algae. When chemically modified, this “alginate” reduces oxidative stress, has an anti-inflammatory effect in cell culture tests and suppresses the immune reaction against cartilage cells, thereby combating the causes of arthritis. The research is, however, still in its infancy.
Osteoarthritis is the most-widespread joint disease, with around 90 percent of all people over 65 being affected to varying degrees, but this degenerative disease is also widespread amongst younger people. In arthritis, the cartilage in the joint, a type of protective layer on bones that “lubricates” the joint, degenerates over time. This can be extremely painful for sufferers, because inflammatory reactions are associated with cartilage degeneration. In the later stages of the disease, bones are no longer adequately protected and can directly rub against each other.
Osteoarthritis can affect all joints in the body, but most often affects the knee joint, hip joint and fingers. The disease has been considered incurable until now. Current treatment methods, such as anti-inflammatory drugs and painkillers, mainly address the symptoms. Often, the only remaining option is an operation to replace the affected joint with an artificial one.
Initial research results are encouraging
In laboratory tests, the team led by ETH researcher Marcy Zenobi-Wong and Empa researcher Katharina Maniura has now succeeded, together with SINTEF in Norway, in identifying a substance with the potential to halt cartilage degeneration in joints. This substance is the polysaccharide alginate extracted from the stems of brown algae – or more precisely cuvie (Lat. Laminaria hyperborea), which is similar to specific extracellular biomolecules in cartilage. The researchers chemically modified the alginate with sulfate groups and then added it in dissolved form to cell cultures to examine the reaction of various cell types to the modified polysaccharide. This revealed that alginate sulfate can significantly reduce oxidative stress, which is a frequent cause of cell damage or even cell death, and the more sulfate groups attached to the alginate molecule, the greater this reduction.
Alginate sulfate was also able to suppress the inflammatory reaction, again depending on the number of sulfate groups, and was able to down-regulate the expression of genes that trigger an inflammatory reaction in both human cartilage cells, known as chondrocytes, and in macrophages, the “scavenger cells” of our immune system. The algal molecules should therefore slow down cartilage degeneration. “The hope is that they can even stop this degeneration,” says Empa researcher Markus Rottmar.
Further research work necessary
The alginate sulfates have so far only been tested in vitro, i.e. in the laboratory with cell cultures. However, the encouraging results mean that research will now continue. The next stage is to test the substances on animals. If this is also successful, clinical trials can then be conducted on people. These tests are, however, laborious and time-consuming. If everything were to work perfectly, it would still be a few years before arthritis patients could be treated with alginate sulfate.
Learn more: Treating arthritis with algae
The Latest on: Osteoarthritis
- Gene therapy cuts fat and builds muscle in sedentary mice on unhealthy dietson May 11, 2020 at 5:55 am
A single injection of the gene that makes the protein follistatin caused a significant buildup of muscle mass in mice while also preventing obesity, reported Washington University researchers. The ...
- 2020 Osteoarthritis Market and Competitive Landscape Analysis - ResearchAndMarkets.comon May 11, 2020 at 4:19 am
This research report provides comprehensive insights into the Osteoarthritis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. The research ...
- Strenuous Exercise Is Safe for People at Risk for Knee Osteoarthritison May 9, 2020 at 6:25 pm
People at risk for knee osteoarthritis (KOA) may have avoided activities that they enjoy like running or biking for no reason. New research suggests that you can reduce your chances of KOA by doing ...
- Vigorous activity or sedentary behaviour is not associated with risk for knee osteoarthritison May 9, 2020 at 12:06 pm
Patients and some clinicians still are concerned that physical activity, particularly vigorous physical activity, might be associated with excess risk for knee osteoarthritis (OA), despite ...
- COVID-19 Impact and Recovery Analysis | Global Osteoarthritis Therapeutics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Anika Therapeutics Inc ...on May 8, 2020 at 6:30 am
The global osteoarthritis therapeutics market is expected to grow by USD 2.99 billion as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact ...
- Polk doctors: Hand pain, stiffness from osteoarthritis can be treatedon May 6, 2020 at 8:22 am
People often deal with the discomfort of osteoarthritis by taking over-the-counter nonsteroidal anti-inflammatory drugs. Over time, if the pain worsens, ...
- Transcriptional profiling of murine macrophages stimulated with cartilage fragments revealed a strategy for treatment of progressive osteoarthritison May 5, 2020 at 6:01 am
Macrophages play principal role in development of synovitis. Our earlier study suggests that interaction between cartilage fragments and macrophages exacerbates osteoarthritic process. However, ...
- Osteoarthritis Action Alliance Announces Launch- A National Public Health Agenda for Osteoarthritis: 2020 Updateon May 4, 2020 at 5:22 am
A National Public Health Agenda for Osteoarthritis: 2020 UpdatePR NewswireCHAPEL HILL, N., May 4, 2020A national policy document that address the burden of OA with actionable solutionsCHAPEL HILL, N.
- Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020on May 1, 2020 at 6:29 am
Flexion Therapeutics, Inc. (FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (triamcinolone acetonide injectable suspension), including an analysis ...
- Osteoarthritis Pain Drugs Market Trends, Share, Size, Growth, Supply and Manufacturers Analysis Research Report 2025on May 1, 2020 at 5:01 am
Kenneth Research has published a detailed report on Osteoarthritis Pain Drugs Market which has been categorized by ...
via Google News and Bing News